BioWorld. Link to homepage.
BioWorld
BioWorld Science
BioWorld Asia
Data Snapshots
Biopharma
Medical technology
Infographics: Dynamic digital data analysis
Index insights
NME Digest
Special reports
Infographics: Dynamic digital data analysis
Ebola outbreak
Hantavirus
Trump administration impacts
Med-tech outlook 2026
Under threat: mRNA vaccine research
BioWorld at 35
Biopharma M&A scorecard
Bioworld 2025 review
BioWorld MedTech 2025 review
BioWorld Science 2025 review
Women's health
China's GLP-1 landscape
PFA re-energizes afib market
China CAR T
Alzheimer's disease
Coronavirus
More reports can be found here
BioWorld. Link to homepage.
Sign In
Sign Out
My Account
Subscribe
BioWorld - Thursday, June 4, 2026
Home
»
Newsletters
» BioWorld Science
BioWorld Science
Jan. 5, 2021
View Archived Issues
Sinopharm CNBG's COVID-19 vaccine approved in China
Read More
Promising phase II data presented for BT-11 in ulcerative colitis
Read More
Nanjing Ruijie Pharma discloses new NR1H4 agonists
Read More
PT-101 shows safety and ability to selectively expand Tregs in healthy volunteers
Read More
Vivoryon Therapeutics patents meprin A inhibitors
Read More
Ayala plans pivotal phase II/III RINGSIDE study of AL-102 in desmoid tumors
Read More
Ryvu Therapeutics identifies hSTING receptor agonists
Read More
Enterprise Therapeutics divulges ANO1 activators
Read More
FDA clears IND for phase I/II study of FBX-101 in patients with Krabbe disease
Read More
Karuna opens enrollment in phase III study of KarXT in acutely psychotic schizophrenia
Read More
Protein introns, "inteins", are antifungal targets
Read More
Pfizer initiates first-in-human study of PF-07209960 for advanced or metastatic solid tumors
Read More
Novartis presents new NPR1-targeting antibodies
Read More
Novel anti-NPM1c CAR-T cells demonstrate efficacy in models of AML
Read More
ID-93/GLA-SE tuberculosis vaccine demonstrates safety and immunogenicity in phase IIa trial
Read More
BET inhibitor ODM-207 is safe in fist-in-human study in patients with solid tumors
Read More
Luye initiates phase I trial of monthly microsphere injection LY-03009
Read More
New phase II trial evaluates SCD-044 for moderate to severe plaque psoriasis
Read More
Topline phase II data reported for ATYR-1923 in hospitalized COVID-19 patients
Read More
Ryvu submits CTA to begin phase I/II trial of RVU-120 in solid tumors
Read More
EMA validates Opdivo filing in first-line gastric cancer, GEJ and esophageal adenocarcinoma
Read More
CANTATA study of telaglenastat in renal cell carcinoma misses primary endpoint
Read More
New phase III trial evaluates tisotumab vedotin for recurrent or metastatic cervical cancer
Read More
